Moderna, Inc. 8-K Report: Key Updates & Insights as of February 14, 2025
Based on the provided section of the financial report, here are the key pieces of information and insights:
- Entity Information:
- Company Name: Moderna, Inc.
- CIK (Central Index Key): 0001682852
- Incorporation State: Delaware (DE)
- SEC File Number: 001-38753
- EIN (Employer Identification Number): 81-3467528
- Address:
- Headquarters: 325 Binney Street, Cambridge, MA 02142
- Contact Number: 617-714-6500
- Filing Information:
- Filing Type: 8-K (Current Report)
- Filing Date: February 14, 2025
- Security Information:
- Common Stock: Par value $0.0001 per share
- Ticker Symbol: MRNA (traded on NASDAQ)
- Reporting Period:
- Report Date: February 14, 2025 (the same as the filing date)
Insights:
- The report is a current report (8-K), which is typically filed to announce major events that shareholders should know about. The timing of the report indicates that it could include significant updates relevant to investors or stakeholders.
- The company is established in Cambridge, Massachusetts, suggesting a potential focus on biotechnology and pharmaceutical innovations, consistent with its core business model.
- As a publicly traded company on NASDAQ, Moderna is subject to continuous regulatory scrutiny and must maintain compliance with SEC reporting requirements. The filing date being the same as the report date may imply the event or information reported is recent and possibly urgent.
- The par value of the common stock is minimal, which is common among companies in the biotech sector, allowing for flexibility in equity financing.
Overall, this filing may indicate an important development or event related to Moderna that could impact its operations or financial performance.